2018 Market Spotlight: Primary Sclerosing Cholangitis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Primary Sclerosing Cholangitis” report has been
added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Primary Sclerosing Cholangitis
market, comprising disease background, treatment overview, key pipeline
drugs, recent events and analyst opinion, upcoming events, clinical
trials, probability of success, and a 10-year global disease prevalence
forecast.

Key Takeaways

• The author estimates that in 2016, there were 227,400 prevalent cases
  of primary sclerosing cholangitis (PSC) worldwide among adults aged 30
  years and over, and forecasts that number to increase to 265,700
  prevalent cases by 2025.
• The majority of industry-sponsored drugs in active clinical
  development for PSC are in Phase II, with only one drug in Phase III.
  Therapies in the pipeline for PSC focus on a wide variety of targets.
  The majority of pipeline drugs in development are administered via the
  oral route, with a smaller number of drugs being tested in intravenous
  and subcutaneous formulations.
• High-impact upcoming events in the PSC space comprise topline Phase II
  trial results for BTT-1023, cenicriviroc, and DUR-928. The overall
  likelihood of approval of a Phase I autoimmune/immunology-other asset
  is 20.2%, and the average probability a drug advances from Phase III
  is 69.4%. Drugs, on average, take 9.8 years from Phase I to approval,
  compared to 8.7 years in the overall autoimmune/immunology space.
• The clinical trials distribution across Phase I-IV indicates that the
  majority of trials for PSC have been in the mid-phase of development,
  with 77.8% of trials in Phase II, and only 11.1% of trials each in
  Phase I and Phase III.
• The US leads in terms of the number of PSC clinical trials globally,
  while the UK leads the major EU markets. Gilead Sciences is the only
  company with more than one clinical trial in the PSC space. The
  company has conducted two Phase II trials.

Topics Covered

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

GS-9674 for PSC (November 9, 2018)

NGM282 for PSC (February 5, 2018)

Ocaliva for PSC (July 31, 2017)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

Trials by status

Trials by phase

Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

Figure 1: Trends in prevalent cases of PSC, 2017-26

Figure 2: Overview of pipeline drugs for PSC in the US

Figure 3: Pipeline drugs for PSC, by company

Figure 4: Pipeline drugs for PSC, by drug type

Figure 5: Pipeline drugs for PSC, by classification

Figure 6: GS-9674 for PSC (November 9, 2018): Phase II – Without
Cirrhosis

Figure 7: NGM282 for PSC (February 5, 2018): Phase II – 15-0106

Figure 8: Ocaliva for PSC (July 31, 2017): Phase II – AESOP

Figure 9: Key upcoming events in PSC

Figure 10: Probability of success in the PSC pipeline

Figure 11: Clinical trials in PSC

Figure 12: Top 10 drugs for clinical trials in PSC

Figure 13: Top 10 companies for clinical trials in PSC

Figure 14: Trial locations in PSC

Figure 15: PSC trials status

Figure 16: PSC trials sponsors, by phase

LIST OF TABLES

Table 1: Prevalent cases of PSC, 2017-26

Table 2: Pipeline drugs for PSC in the US

Table 3: GS-9674 for PSC (November 9, 2018)

Table 4: NGM282 for PSC (February 5, 2018)

Table 5: Ocaliva for PSC (July 31, 2017)

For more information about this report visit https://www.researchandmarkets.com/r/tq9gzr

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs